TIRZEPATIDE (Mounjaro, Zepbound) prior authorization at UnitedHealthcare
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
UnitedHealthcare requires Glucose-dependent Insulinotropic Polypeptide Receptor Agonist prior-authorization documentation for TIRZEPATIDE (Mounjaro, Zepbound): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 180 days to appeal.
The PA criteria you'll need to meet
UnitedHealthcare reviews TIRZEPATIDE (Mounjaro, Zepbound) prior authorizations against its medical policy for Glucose-dependent Insulinotropic Polypeptide Receptor Agonist. UnitedHealthcare-specific context: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Glucose-dependent Insulinotropic Polypeptide Receptor Agonist
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- UnitedHealthcare's medical policy URL referenced in the cover letter
UnitedHealthcare's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- GLP-1 weight-loss exclusion
- Out-of-network reduction citing UCR
- Step therapy on biologics
- Prior auth denied for advanced imaging
- Quantity limits on specialty drugs
TIRZEPATIDE (Mounjaro, Zepbound)-specific denial patterns and context
Across payers (not just UnitedHealthcare), TIRZEPATIDE (Mounjaro, Zepbound)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- Weight-loss exclusion (Zepbound)
- Step therapy requiring GLP-1 first
- Quantity limit
Sold as Mounjaro (T2D) and Zepbound (chronic weight management). Dual GIP/GLP-1 receptor agonist.
Manufacturer patient-assistance program: Lilly Cares — relevant when a UnitedHealthcare denial sticks and the patient needs bridge access while appealing.
How UnitedHealthcare approaches GLP-1 receptor agonists PAs
UnitedHealthcare's GLP-1 receptor agonists reviewer typically anchors TIRZEPATIDE (ZEPBOUND) prior-auth decisions on glp-1 weight-loss exclusion and step therapy on biologics. Pharmacy-benefit review for TIRZEPATIDE (ZEPBOUND) at UnitedHealthcare is routed through OptumRx (in-house PBM, parent UnitedHealth Group). The 30-day standard review window starts when the prior-authorization request is received with all required documentation — incomplete packets pause the clock and add 5-10 days to time-to-approval, after which the 180-day internal-appeal window begins from the denial date. Plans including UnitedHealthcare commonly distinguish T2D-indication PAs (Ozempic, Mounjaro, Trulicity) from weight-management-indication PAs (Wegovy, Zepbound, Saxenda) — the second path triggers benefit-exclusion review under the plan's anti-obesity-medication carve-out language. UnitedHealthcare is domiciled in MN, so unresolved appeals escalate to the MN insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead). UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest.
Medical policy for TIRZEPATIDE (Mounjaro, Zepbound)
UnitedHealthcare publishes a public medical-policy reference for TIRZEPATIDE (Mounjaro, Zepbound). Cite the specific policy number and revision date in the cover letter so the reviewer can locate the criteria without paging through the policy index: https://www.uhcprovider.com/en/policies-protocols/pharmacy-policies.html.
If the PA is denied
UnitedHealthcare gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.uhcprovider.com) with the same packet plus a peer-reviewed citation supporting TIRZEPATIDE (Mounjaro, Zepbound)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a UnitedHealthcare denial on DenialHelp.
Contact UnitedHealthcare
- Provider portal: https://www.uhcprovider.com
Frequently asked questions
What documentation does UnitedHealthcare need for TIRZEPATIDE (Mounjaro, Zepbound) prior auth?
UnitedHealthcare's typical PA packet for TIRZEPATIDE (Mounjaro, Zepbound): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Glucose-dependent Insulinotropic Polypeptide Receptor Agonist, expect clinical-criteria documentation specific to this class.
What's the turnaround time at UnitedHealthcare?
Standard TIRZEPATIDE (Mounjaro, Zepbound) PA decisions at UnitedHealthcare: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does UnitedHealthcare most often reject TIRZEPATIDE (Mounjaro, Zepbound) for?
Across UnitedHealthcare's book the common rejection patterns include: GLP-1 weight-loss exclusion; Out-of-network reduction citing UCR; Step therapy on biologics. For TIRZEPATIDE (Mounjaro, Zepbound) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
Why does UnitedHealthcare require specific BMI documentation for TIRZEPATIDE (ZEPBOUND)?
UnitedHealthcare's GLP-1 prior-auth policy distinguishes T2D-indication submissions (A1C-based criteria) from weight-management-indication submissions (BMI ≥30, or ≥27 with weight-related comorbidity, matching the FDA label). For weight-management TIRZEPATIDE (ZEPBOUND) the reviewer also screens for the plan's anti-obesity-medication exclusion — submit the chart note with BMI, weight-related comorbidity (HTN, dyslipidemia, T2D, OSA, OA), and either (a) ≥6 months of documented lifestyle intervention or (b) a documented reason intensive lifestyle was inappropriate. 30-day standard decision, 180-day appeal window. Pharmacy-benefit handling is routed through OptumRx (in-house PBM, parent UnitedHealth Group). External-review escalation for UnitedHealthcare fully-insured policies sits with the MN insurance department.
How do I prep for a peer-to-peer with UnitedHealthcare on TIRZEPATIDE (Mounjaro, Zepbound)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the TIRZEPATIDE (Mounjaro, Zepbound) PA packet
Open ApprovalHelp — generate a TIRZEPATIDE (Mounjaro, Zepbound) prior-auth packet tailored to UnitedHealthcare's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com